Paper 13407-61
Performance evaluation of a stacked classifier for predicting treatment response in unresectable colorectal liver metastases
19 February 2025 • 5:30 PM - 7:00 PM PST | Golden State Ballroom
Abstract
Colorectal cancer is the third most common cancer worldwide. Approximately 50\% of these patients will develop liver metastases. Neoadjuvant chemotherapy is used to reduce size of metastases so that patients are eligible for potentially curative resection. Our study demonstrates that baseline CT scans can be used to predict response prior to initiation of chemotherapy. We analyzed baseline CT images of 342 patients with unresectable colorectal liver metastases (CRLM) who received chemotherapy at Memorial Sloan Kettering Cancer Center (MSK) or University of Texas MD Anderson Cancer Center (MDA). We predicted response as defined by Response Evaluation Criteria in Solid Tumors (RECIST). Different classifiers were evaluated, and the three best-performing ones were selected. Further, these were later combined in a stacking classifier to improve prediction accuracy. Naive Bayes showed the best performance with an accuracy of 0.745 and AUC of 0.785 when trained on features extracted from all tumors. The stacking classifier demonstrated a slightly better precision (0.742) and specificity (0.742).
Presenter
Queen's Univ. (Canada)
Amber Simpson is the Canada Research Chair in Biomedical Computing and Informatics, and Associate Professor jointly appointed in the Department of Biomedical and Molecular Sciences and School of Computing at Queen’s University. She is an Affiliate of the Vector Institute for AI as well as a Senior Investigator at the Canadian Cancer Trials Group. Dr. Simpson is the Director of the Centre for Health Innovation, a joint venture with Kingston Health Sciences Centre and Queen’s. She received her PhD in Computer Science from Queen’s and was a postdoctoral fellow in the Department of Biomedical Engineering at Vanderbilt University. She holds research funding from the National Institutes of Health as well funding from all three Canadian research councils. Dr. Simpson is an American Association of Cancer Research and Pancreatic Cancer Action Network award holder and a charter member of NIH study s